Published in Int J Cancer on August 09, 1995
Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci U S A (1997) 0.91
Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A. World J Gastroenterol (2001) 0.86
T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant. Immunology (1997) 0.81
The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity. PLoS One (2013) 0.81
Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J Immunol (1989) 2.32
Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J (1995) 1.99
Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry (1986) 1.57
Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J (1995) 1.54
Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells. J Immunol (1990) 1.51
Long-term effects of neonatal estrogen treatment on mitogen responsiveness of mouse spleen lymphocytes. J Natl Cancer Inst (1979) 1.49
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. J Immunol (1998) 1.30
Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med (1995) 1.30
A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells. J Immunol (1991) 1.29
Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. J Immunol (1997) 1.29
The crystal structure of staphylococcal enterotoxin type D reveals Zn2+-mediated homodimerization. EMBO J (1996) 1.23
Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A (1991) 1.22
In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors. Proc Natl Acad Sci U S A (1996) 1.21
Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. J Immunol (1992) 1.17
Characterization of individual tumor necrosis factor alpha-and beta-producing cells after polyclonal T cell activation. J Immunol Methods (1989) 1.14
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology (1993) 1.13
Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. J Immunol (1987) 1.13
Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer (1993) 1.11
Superantigens anergize cytokine production but not cytotoxicity in vivo. Immunology (1994) 1.10
Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor. Eur J Immunol (1991) 1.09
T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol (1995) 1.07
Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol (1985) 1.06
Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol (1996) 1.05
Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T cells. Cell Immunol (1991) 1.05
Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology (1990) 1.03
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci U S A (1995) 1.03
Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother (1993) 1.03
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol (1997) 1.02
Staphylococcal-enterotoxin-dependent cell-mediated cytotoxicity. Immunol Today (1991) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. Scand J Gastroenterol (1999) 1.00
Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother (1995) 0.99
Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. Cell Immunol (1996) 0.99
Phenotypical and functional differentiation of CD4+ CD45RA+ human T cells following polyclonal activation. Scand J Immunol (1990) 0.98
Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Am J Pathol (1997) 0.98
Outcomes of periradicular surgery in cases with apical pathosis and untreated canals. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 0.96
Rapid and specific detection of PCR products using light-up probes. Mol Cell Probes (2000) 0.95
Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol (1993) 0.95
Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res (1986) 0.95
Histamine inhibits interleukin 1 production by lipopolysaccharide-stimulated human peripheral blood monocytes. Scand J Immunol (1988) 0.95
Superantigen activation of CD4+ and CD8+T cells from HIV-infected subjects: role of costimulatory molecules and antigen-presenting cells (APC) Clin Exp Immunol (1998) 0.95
Staphylococcal enterotoxin H displays unique MHC class II-binding properties. J Immunol (1999) 0.94
The LFA-3 adhesion pathway is differently utilized by superantigen-activated human CD4+ T-cell subsets. Scand J Immunol (1992) 0.94
Lymphoid hyperplasia in transgenic mice over-expressing a secreted form of the human interleukin-1beta gene product. Immunology (1999) 0.93
Effect of estrogen and corticosterone on the lymphoid system in neonatal mice. Exp Mol Pathol (1978) 0.93
Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer (2001) 0.93
Staphylococcal enterotoxin D is a promiscuous superantigen offering multiple modes of interactions with the MHC class II receptors. J Immunol (1998) 0.93
Superantigen-induced anergy in cytotoxic CD8+ T cells. J Immunol (1995) 0.92
Role of the adhesion molecule ICAM-1 (CD54) in staphylococcal enterotoxin-mediated cytotoxicity. Eur J Immunol (1991) 0.92
Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol (1994) 0.91
Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR+ mononuclear leukocytes and freshly prepared leukemia cells. Cell Immunol (1990) 0.91
A critical evaluation of the calcium balance technic. 3. The theoretical phosphorus balance. Metabolism (1967) 0.91
Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity. Curr Top Microbiol Immunol (1991) 0.91
Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. Adv Exp Med Biol (2000) 0.91
Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci U S A (1997) 0.91
The Co-crystal structure of staphylococcal enterotoxin type A with Zn2+ at 2.7 A resolution. Implications for major histocompatibility complex class II binding. J Biol Chem (1996) 0.90
Non-palpable inguinal hernia in the female. Am Surg (1988) 0.90
Reduced natural killer activity in female mice after neonatal exposure to diethylstilbestrol. J Immunol (1980) 0.89
Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity. Immunology (1993) 0.89
Rapid response to Con A by CD4+CD45R- rat memory lymphocytes as compared to CD4+CD45R+ lymphocytes. Cell Immunol (1989) 0.89
The role of B7-1 and LFA-3 in costimulation of CD8+ T cells. J Immunol (1997) 0.88
CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. J Biol Chem (1999) 0.88
Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth. Int J Cancer (1998) 0.88
Staphylococcal protein A (SpA) does not induce production of interferon-gamma in human mononuclear blood cells. Cell Immunol (1984) 0.88
Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem (1993) 0.88
Allogeneic heart transplantation activates alloreactive NK cells. Cell Immunol (1997) 0.87
Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II. J Immunol (1996) 0.87
Postembryonic differentiation of serotonin-immunoreactive neurons in fleshfly optic lobes developing in situ or cultured in vivo without eye discs. J Comp Neurol (1987) 0.86
Monocyte-regulated IFN-gamma production in human T cells involves CD2 signaling. J Immunol (1993) 0.86